What Is the Survival Rate of Ovarian Cancer?

Ovarian cancer survival depends heavily on stage at diagnosis, with five-year rates ranging from roughly 87% for stage I disease down to about 14% for stage IV. Because the majority of cases are found after the cancer has already spread beyond the ovaries, the overall picture is grimmer than the early-stage numbers suggest. Tumor type, the completeness of surgery, genetic factors like BRCA mutations, and even which hospital performs the operation all shift the odds in ways that matter to individual patients.

Survival by Stage at Diagnosis

Stage is the single strongest predictor of how long someone with ovarian cancer will live. A large prospective UK study found five-year survival of 87% for stage I, 62% for stage II, 26% for stage III, and 14% for stage IV.¹ Those figures align closely with a separate analysis of over 4,000 patients restaged under the 2013 FIGO classification, which reported five-year survival of 87% for stage IA, around 75–80% for stage IB through IC3, roughly 61–65% for stage II, 22% for stage IIIC, and about 13–14% for stage IV.²

The problem is that most ovarian cancers are not caught early. The disease rarely causes obvious symptoms in its initial stages, and no screening method has been shown to reduce deaths. The largest randomized screening trial ever conducted, the UK Collaborative Trial of Ovarian Cancer Screening, followed over 200,000 women and found no significant reduction in ovarian cancer deaths whether women were screened with blood tests, ultrasound, or both.³ Without effective screening, about three-quarters of women are diagnosed at stage III or IV, which is the main reason overall survival statistics remain discouraging compared to many other cancers.

How Tumor Type Changes the Numbers

Not all ovarian cancers behave the same way. The most common form, high-grade serous carcinoma, accounts for roughly 70% of epithelial ovarian cancers and tends to present at advanced stages. It responds well to platinum-based chemotherapy initially but frequently recurs. Clear cell carcinoma, a less common subtype, tells a different story depending on stage. At early stages, clear cell tumors have an excellent prognosis, with three-year overall survival above 90% for stage IA.⁴ But when diagnosed at advanced stages, clear cell carcinoma fares worse than serous tumors, with a meta-analysis finding a meaningfully higher hazard of death for stage III and IV clear cell disease compared with serous cancer.⁵ The reason: clear cell tumors are more resistant to standard platinum chemotherapy, so the usual fallback when surgery cannot remove everything is less effective.

Non-epithelial ovarian cancers, which include germ cell tumors and sex cord-stromal tumors, are far less common but generally carry a much better prognosis. In a Danish population study covering nearly four decades, five-year survival was 94% for germ cell tumors and 79% for sex cord-stromal tumors in the most recent period examined.⁶ Germ cell tumors tend to strike younger women and respond very well to chemotherapy. For patients treated with fertility-sparing surgery, long-term disease-free survival rates of about 91% at five years and 83% at ten years have been reported.⁷

Why Surgical Completeness Matters So Much

For advanced ovarian cancer, the goal of surgery is cytoreduction: removing as much visible tumor as possible. How much disease is left behind after surgery is one of the most powerful predictors of how long someone will live. A meta-analysis pooling data from dozens of studies found that women left with no macroscopically visible residual disease had a median overall survival of about 50 months. Women with even a small amount left behind, up to one centimeter, had a median survival roughly 18 months shorter. And women with more than two centimeters of remaining tumor had the worst outcomes.⁸

A Cochrane systematic review confirmed the pattern, finding that women with any visible residual disease after primary surgery had about twice the risk of death compared with those in whom all visible tumor was removed.⁹ A nationwide Norwegian study found similarly that residual disease roughly doubled or tripled the risk across different tumor types.¹⁰ This is why the skill of the surgeon and the resources of the hospital play such an outsized role in ovarian cancer outcomes, a point covered in more detail below.

Chemotherapy Timing and Targeted Treatments

The standard first-line treatment for advanced ovarian cancer is a combination of surgery and platinum-based chemotherapy. One of the ongoing debates is whether surgery should come first (primary debulking) or whether chemotherapy should shrink the tumor before operating (neoadjuvant chemotherapy followed by interval surgery). A recent systematic review and meta-analysis of randomized trials found that the two approaches produced equivalent overall survival, while neoadjuvant chemotherapy led to significantly fewer severe surgical complications and a higher rate of complete tumor removal.¹¹ The landmark European trial that first established this equivalence reported a hazard ratio for death of 0.98, meaning essentially no difference.¹² That said, some observational data suggest primary surgery may offer a modest edge in selected patients: one single-institution comparison found five-year survival of 39% with upfront surgery versus 27% with neoadjuvant chemotherapy, though selection bias makes that comparison difficult to interpret cleanly.¹³ In practice, the decision often hinges on whether complete cytoreduction looks achievable upfront.

PARP Inhibitors

PARP inhibitors have been the most significant drug advance in ovarian cancer in years. These drugs block a DNA repair pathway that cancer cells rely on when they already have defects in another repair pathway, particularly those caused by BRCA mutations. The benefit in progression-free survival is striking: a meta-analysis of BRCA-mutated ovarian cancer patients found that adding a PARP inhibitor to conventional therapy reduced the hazard of disease progression by about two-thirds. The gain was largest when given as first-line maintenance after initial treatment, extending median progression-free survival by about 22.5 months compared with roughly 9.6 months in the recurrent setting.¹⁴ Whether that translates into longer overall survival has been harder to prove statistically, partly because patients in control arms often crossed over to PARP inhibitors later. Data from multiple first-line maintenance trials confirm the greatest benefit is in women with BRCA mutations or whose tumors test positive for homologous recombination deficiency.¹⁵

Bevacizumab

Bevacizumab, a drug that blocks the formation of new blood vessels that tumors need to grow, has also been tested extensively in ovarian cancer. The evidence is nuanced. Two large phase III trials showed modest improvements in progression-free survival when bevacizumab was added to chemotherapy, but no clear overall survival benefit for the full study populations.¹⁶ However, in exploratory analyses of women with the poorest-prognosis disease, bevacizumab added meaningfully to survival. The GOG-0218 trial found that for stage IV patients, median overall survival improved from roughly 33 months without bevacizumab to about 43 months with it.¹⁷ The ICON7 trial likewise found a survival advantage limited to a poor-prognosis subgroup.¹⁶ So bevacizumab does not help everyone, but it appears to help the women who need it most.

Heated Intraperitoneal Chemotherapy

Heated intraperitoneal chemotherapy, or HIPEC, delivers chemotherapy directly into the abdominal cavity at elevated temperatures during surgery. A Dutch randomized trial found that adding HIPEC to interval cytoreductive surgery improved median overall survival from about 34 months to nearly 46 months.¹⁸ A follow-up randomized trial confirmed a similar benefit in the interval surgery setting, with median overall survival extending from about 48 months to nearly 62 months.¹⁹ HIPEC is gaining traction but is still not uniformly available, and the evidence is strongest for patients who have responded to upfront chemotherapy and then undergo surgery.

BRCA Mutations and Survival

Women with BRCA1 or BRCA2 mutations face a higher lifetime risk of developing ovarian cancer, but somewhat paradoxically, their cancers may respond better to treatment in the short term. A large study found that carrying a BRCA mutation was associated with a roughly 30% lower hazard of death in the first three years after diagnosis. But this advantage faded over time; at ten years, there was no detectable survival difference between carriers and noncarriers. Among women with serous ovarian cancer specifically, about 27% of both carriers and noncarriers were alive 12 years after diagnosis.²⁰

That said, BRCA2 carriers may do better than BRCA1 carriers. One study found a five-year survival rate of 61% for BRCA2 carriers compared with 25% for women without either mutation, a statistically significant difference that held after adjusting for other factors. BRCA1 carriers had a more modest and statistically uncertain advantage that disappeared once age was accounted for.²¹ These findings predate the widespread use of PARP inhibitors, which specifically exploit the DNA repair defects in BRCA-mutated tumors. With PARP inhibitors now standard maintenance therapy for BRCA carriers, the survival gap between carriers and noncarriers may be widening further in carriers’ favor, though long-term data are still maturing.

The Effect of Age

Younger women consistently survive ovarian cancer longer than older women, even within the same stage. Population-based data show that for advanced disease (stages III and IV), women under 45 have a five-year relative survival above 45%, compared with only about 8% for those 85 and older.²² Part of that gap is explained by older women being less likely to receive aggressive surgery or full-dose chemotherapy. But even after accounting for differences in tumor characteristics and treatment, elderly women still carry a substantially higher risk of dying, with one study estimating a nearly two-fold increase compared with younger patients.²³ Biological differences in tumor behavior, reduced tolerance for treatment side effects, and the presence of other health conditions all contribute.

Racial and Socioeconomic Disparities

Ovarian cancer survival is not equitable. A meta-analysis including over 190,000 patients found that Black women had an 18% higher risk of death compared with white women. Lower socioeconomic status was associated with a 10% increase in mortality risk.²⁴ These gaps are driven in large part by unequal access to treatment. The same meta-analysis found that Black women were about 25% less likely to receive ovarian cancer treatment than white women, and women in the lowest socioeconomic bracket were about 15% less likely to receive guideline-concordant care.²⁵ Insurance status, geographic access to gynecologic oncologists, and differences in referral patterns all play a role. These disparities are not about biology; they are about who gets the standard of care and who does not.

Recurrence and Platinum Sensitivity

Even when treatment initially succeeds, ovarian cancer recurs in roughly 70% of cases.²⁶ When recurrence happens matters. If the cancer returns more than six months after the last platinum-based chemotherapy, it is considered platinum-sensitive, and retreatment with platinum drugs tends to work again. If it returns sooner, it is labeled platinum-resistant, a situation with far fewer effective options and a much worse prognosis.²⁷

For platinum-sensitive recurrence, PARP inhibitor maintenance after retreatment can extend the time before the next relapse. Bevacizumab combined with chemotherapy improves progression-free survival in the recurrent setting as well, though without a clear overall survival benefit. For platinum-resistant disease, newer antibody-drug conjugates are emerging: mirvetuximab soravtansine, which targets a protein called folate receptor alpha, improved both progression-free survival and overall survival compared with chemotherapy alone in a recent phase III trial of women with platinum-resistant disease whose tumors expressed that receptor at high levels.²⁶ This is one of the first drugs to demonstrate a true survival benefit specifically in platinum-resistant ovarian cancer, a space that badly needed one.

Conditional Survival Improves Over Time

One underappreciated piece of good news: the longer someone survives after an ovarian cancer diagnosis, the better their odds of continued survival become. This concept, called conditional survival, reflects the fact that the highest risk of death concentrates in the first few years. An analysis of SEER data found that for women with stage IV disease, the probability of surviving another five years more than tripled, from 17% at diagnosis to 56% after already surviving five years.²⁸ Among patients with undifferentiated tumors, five-year conditional survival jumped from 29% at diagnosis to 84% after five years of survival. This is meaningful information for patients who have made it through treatment and are living with the anxiety of recurrence. The numbers get better with each passing year.

Where You Get Treated Makes a Difference

The hospital and surgeon performing ovarian cancer surgery have a measurable effect on outcomes. A recent systematic review found that treatment at high-volume hospitals was associated with significantly better overall survival in 13 out of 15 studies examined. The differences were large: reported five-year survival rates ranged from about 22% at low-volume hospitals to 55% at high-volume centers. Perioperative mortality was also lower, and rates of complete tumor removal were consistently higher at experienced centers.²⁹

Surgeon specialty matters too. Research has found that having the initial surgery performed by a gynecologic oncologist was associated with about a 30% reduction in the risk of death compared with surgery by a non-specialist.³⁰ A systematic review estimated that treatment by a gynecologic oncologist at a specialized hospital provided a five- to eight-month median survival advantage for patients with advanced disease.³¹ This is one of the most actionable pieces of information for anyone navigating a new diagnosis: if possible, seek care at a high-volume cancer center with gynecologic oncology expertise.

How Survival Trends Have Changed Over Decades

Ovarian cancer survival has improved over time, but the gains have been gradual rather than dramatic. An analysis of U.S. SEER data from 1975 to 2011 found significant reductions in mortality risk at every stage over that period. Women with advanced disease diagnosed in 2006 had about half the excess hazard of death compared with those diagnosed in 1975.³² A separate analysis of about 75,000 patients from the SEER database confirmed that both incidence and cancer-specific mortality decreased between 2000 and 2017, with the authors attributing the improvement largely to advances in diagnosis and treatment.³³

There is a caveat, though. A Dutch population study covering 1989 to 2014 found that while five-year survival improved modestly for both early-stage (from 74% to 79%) and advanced-stage (from 16% to 24%) disease, ten-year survival barely budged, remaining at about 24% for all stages combined.³⁴ The implication is sobering: better treatments have pushed recurrences later and extended the time before death, but for many women with advanced disease, the cancer still eventually comes back. The introduction of PARP inhibitors and HIPEC came largely after the periods covered by these trend studies, so whether they will bend the long-term survival curve remains one of the most important open questions in gynecologic oncology.